Abstract
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor which requires heterodimerization with the Ah receptor nuclear translocator (Arnt) for function. Arnt is also a dimerization partner of the hypoxia inducible factor 1α (HIF-1α) for the hypoxia signaling. Additionally, Arnt is found to be a potent coactivator of the estrogen receptor (ER) signaling. Thus we examined whether the presence of an increased amount of AhR may suppress both the HIF-1α and ER signaling pathways by sequestering Arnt. We tested our hypothesis using a human AhR construct CΔ553 which is capable of heterodimerizing with Arnt in the absence of a ligand. Transient transfection studies using a corresponding luciferase reporter plasmid in MCF-7 cells showed that CΔ553 effectively suppressed the AhR, HIF-1α, and ER signaling pathways. Reverse transcription/real-time QPCR data showed that CΔ553 blocked the up-regulation of the target genes controlled by AhR (CYP1A1), HIF-1α (VEGF, aldolase C, and LDH-A), and ER (GREB1, pS2, and c-myc) in MCF-7 cells. Since both HIF-1α and ER are highly active in the ER-positive breast cancer, CΔ553 has the potential to be developed as a protein drug to treat breast cancer by blocking these two signaling pathways. Keywords: Estrogen receptor; Ah receptor; Arnt; HIF-1α; GREB1; protein drugs

This publication has 53 references indexed in Scilit: